MEMBRANE AUTOTRANSFUSION SYSTEM

术中自体输血系统（IOAT）从患者体内抽取废血， 手术伤口部位，净化并将其返回给同一患者。 我们 开发并在体内评估了一种新的IOAT系统， 采用中空纤维膜对抽吸的废血进行净化 超滤器/血浆过滤器，而不是使用离心机，并返回 在闭环连续在线中将纯化的全血输送给患者 在数分钟内完成手术，不会浪费大量血液 细胞和凝血因子。 膜式自体血液回输系统的初步体内评价 （MATS）在小牛人工心室植入过程中有铅 重新定义设计参数。 我们重建了我们的垫子 可以响应快速变化的操作条件，例如 血液流速（0至2，000 ml/min）、血细胞比容（0至45%）、空气栓塞和 泡沫，大团聚体，灌洗液，剪切速率，跨膜 压力、手术持续时间和全身肝素化。 第一阶段涉及使用小牛和人血进行的广泛体内研究 目的是建立性能的一致性， 系统响应操作条件的快速变化。 阶段- II涉及（i）全人工心脏植入期间的评价 小牛研究，和（ii）10头小牛，其中出血将 模拟开放胸腔，流出的血液将被回收， 我们的膜式自体输血系统 预计总可用市场 在美国超过120，000，000美元，这是一个强烈的需求 鉴于目前供体输血相关的恐慌， 艾滋病和肝炎的传播。

Intraoperative autotransfusion system (IOAT) aspirates waste blood from surgical wound site, purifies and returns it to the same patient. We developed and evaluated in-vivo a new IOAT system which is designed to purify the aspirated waste blood using hollow fiber membrane ultrafilter/plasma filters instead of using centrifuges, and return the purified whole blood to the patient in a closed loop continuous on line operation within a few minutes without significant wastage of blood cells and clotting factors. Preliminary in-vivo evaluations of our Membrane Autotransfusion System (MATS) during implantation of artificial ventricles in calves have lead us to redefine the design parameters. We rebuilt our MATS so that it could respond to the rapidly changing operating conditions, such as blood flow rate (o to 2,000 ml/min, hematocrit (o to 45%), air emboli & froth, macroaggregates, irrigating fluid, shear rate, transmembrane pressure, duration of operation, and systemic heparinization. Phase-I involves extensive in-vivo studies using calf and human blood with an objective to establish the consistency of performance of the system in response to the rapid changes in operating conditions. Phase- II involves evaluations (i) during total artificial heart implantation studies in calves, and (ii) in ten calves, where bleeding will be simulated in open chest cavity, and the shed blood will be salvaged by our membrane autotransfusion system. Total available market is expected to be over $120,000,000 in the U.S. There is a strong need for this device in view of the present scare in donor blood transfusions related to transmission of AIDS and hepatitis.